美国BioReliance 　
　BioReliance总部设在马里兰州，其主要向制药、生物制药、诊断和其他生命科学领域的客户提供生物学、专门毒理学和动物健康测试。公司2010年全年收入约1.1亿美元，预计2011年有两位数增长。

BioReliance provides testing and manufacturing services to pharmaceutical and biopharmaceutical companies that span the product cycle from early pre-clinical development to licensed production.

Our goal is to advance the development and delivery of healthcare and consumer products by providing the highest quality testing, development and manufacturing services in partnership with clients worldwide.

BioReliance has provided outsourced services to thousands of customers from most healthcare disciplines, including nearly all of the largest pharmaceutical, biopharmaceutical, and chemical companies in the world. BioReliance is the largest provider of safety testing services focused on the rapidly growing biologics sector of the pharmaceutical and biotechnology industries.

For established biotechnology and pharmaceutical companies, outsourcing to BioReliance streamlines product development and reduces time to market. The Company also enables emerging and clinical stage companies who may lack the staff, expertise and financial resources to conduct many aspects of product development in-house.

Unless otherwise stated or requested, all studies conducted by BioReliance are performed in compliance with the requirements of the UK and German GLP Regulations, the US FDA Good Laboratory Practice Regulations (21 CFR 58), the Japanese GLP Standard and the OECD Principles of Good Laboratory Practice. BioReliance is fully accredited for GLP. To date, many products licensed by the FDA, EMEA and other international agencies have been tested and validated by BioReliance.

All of our studies are conducted under strict confidentiality.